Recombinant Human Solute carrier organic anion transporter family member 1B1 (SLCO1B1), partial

Code CSB-YP896932HU
MSDS
Size Pls inquire
Source Yeast
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP896932HU
MSDS
Size Pls inquire
Source E.coli
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP896932HU-B
MSDS
Size Pls inquire
Source E.coli
Conjugate Avi-tag Biotinylated
E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-BP896932HU
MSDS
Size Pls inquire
Source Baculovirus
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-MP896932HU
MSDS
Size Pls inquire
Source Mammalian cell
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
>85% (SDS-PAGE)
Target Names
SLCO1B1
Uniprot No.
Alternative Names
Liver-specific organic anion transporter 1; LST-1; LST1; OATP-2; OATP-C; OATP1B1; OATPC; SLC21A6; SLCO1B1; SO1B1_HUMAN; Sodium-independent organic anion-transporting polypeptide 2; Solute carrier family 21 member 6; Solute carrier organic anion transporter family member 1B1
Species
Homo sapiens (Human)
Protein Length
Partial
Tag Info
Tag type will be determined during the manufacturing process.
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer before Lyophilization
Tris/PBS-based buffer, 6% Trehalose, pH 8.0
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene References into Functions
  1. SLCO1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms may not be useful as genetic markers of lipid-lowering response to simvastatin therapy. PMID: 29575099
  2. Neither the ABCB1 C3435T nor the SLCO1B1 T521C polymorphism affected edoxaban PK. PMID: 27897269
  3. Subjects with SLCO1B1 c.388AG and c.388GG genotypes (i.e., increased OATP1B1 transport activity for certain substrates) had lower concentrations of CPI than those with SLCO1B1 c.388AA. PMID: 29777022
  4. Advanced pancreatic cancer patients with advanced pancreatic cancer with the solute carrier organic anion transporter family member 1B1 (SLCO1B1) rs4149086 AG or GG genotype may obtain good clinical results when treated with S-1-containing regimens. PMID: 29683977
  5. Study determined that SLCO1B1 rs4149056 T/C genotype and C allele may be associated with exudative age-related macular degeneration, as well as with elevated serum SLCO1B1 levels. Also, higher serum SLCO1B1 levels were found to be associated with early and exudative age-related macular degeneration. PMID: 30010042
  6. OATP1B1 genetic polymorphism is associated with decreased uptake of tamoxifen and its metabolite, endoxifen. PMID: 28627631
  7. SLCO1A2 and SLCO1B1 gene treatment over time interactions were associated with gametocytemia clearance rate. PMID: 28975866
  8. SLCO1B1 rs4149056 genetic variants can affect the HD-MTX-related toxicity in Chinese patients with NHL. PMID: 29095107
  9. This nested case-control study showed that rs4149056 (SLCO1B1, 521T > C) was associated with rosuvastatin-induced myotoxicity in Chinese patients, and that 521C mutant allele increased the risk of rosuvastatin-associated myotoxicity. PMID: 28812116
  10. There is lower prevalence of statin-induced myopathy-linked C allele of rs4149056 in SLCO1B1 gene in Emirati population, compared to Caucasians and Africans. PMID: 29534995
  11. sorafenib-beta-D-glucuronide transport by OATP1B1 or murine Oatp1b2 was effectively inhibited by rifampin. PMID: 28371445
  12. SLCO1B1 and ABCG2 polymorphisms are better predictors of rosuvastatin exposure than ethnicity alone and could be considered in precision medicine dosing of rosuvastatin. PMID: 28385543
  13. results suggested that Gly71Arg and Asn130Asp mutations in UGT1A1 and OATP2 genes might be involved in the development of hyperbilirubinemia in neonates. PMID: 26960716
  14. This review describes what is currently known regarding SLCO1B1 genotype, OATP1B1 protein expression and interindividual and interethnic consequences to drug disposition, with particular focus on statin pharmacokinetics and implications for drug response and toxicity--{REVIEW} PMID: 27936281
  15. Data suggest that OATP1B1, OATP1B3, and OATP2B1 participate in transport of perfluoroalkyl acids in hepatocytes; environmental pollutants transported include PFBS (perfluorobutane sulfonate), PFHxS (perfluorohexane sulfonate), and PFOS (perfluorooctane sulfonate). PMID: 28013215
  16. Associations between SLCO1B1 521C and cholesterol response were not detected in African Americans (n = 333). Associations between CYP3A4*22 or CYP3A5*3 and cholesterol response were not detected in whites or African Americans. PMID: 28482130
  17. Although we have found quite a large number of genetic variants of the UGT1A1 and SLCO1B1 genes in the African-American population, it does not appear that they have a significant impact on the incidence of hyperbilirubinemia among this group of infants. PMID: 27977017
  18. We compared the carrier frequency of Cytochrome P450 Enzymes and Transport Proteins markers among the Russian population living in Moscow with Dagestan ethnic groups. Statistically significant differences for the following gene polymorphisms: CYP2C19*17, CYP2C9*3, ABCB1 (C3435T), SLCO1B1*5 were found between the Russian population and the three ethnic groups of the Dagestan republic. PMID: 29023140
  19. plasma rifampicin concentrations did not differ significantly between the various genotypes of the rs4149032 polymorphism of the SLCO1B1 gene in a South Indian population PMID: 27510251
  20. OATP1B1 showed high interindividual variability in relative protein expression but no statistically significant difference among the studied age groups. PMID: 27098745
  21. Organic anion-transporting polypeptides exert strong impact on disposition and toxicity of antitumor drugs. (Review) PMID: 27449599
  22. SLCO1B1*5 allele variants and patient age predict the likelihood of young women with breast cancer developing chemotherapy-induced amenorrhea. PMID: 27234217
  23. SLCO1B1 polymorphisms appear to be associated with the development of adverse drug reactions to regorafenib. PMID: 28157071
  24. Polymorphisms in SLCO1B1 and UGT1A1 are associated with several different sorafenib side effects PMID: 27533851
  25. OATP1A2, OATP1B1, and OATP2B1 can mediate cellular uptake of ochratoxin A, which could aggravate OTA toxicity. PMID: 28532671
  26. Our results did not indicate a strong association between OATP1B1 or OATP1B3 inhibition and hyperbilirubinemia PMID: 28063966
  27. Polymorphisms of the SLCO1B1 gene ate used for predicting risk of adverse events when using statins. PMID: 28252633
  28. Critical amino acid residues in the predicted transmembrane pore influencing transport kinetics of the hepatic drug transporter OATP1B1 have been identified. PMID: 27594653
  29. Genetic polymorphisms of the UGT1A1 promoter, specifically the T-3279G phenobarbital-responsive enhancer module and (TA)7 dinucleotide repeat, as well as the intron and coding region variants of the OATP2, HMOX1, and BLVRA genes, were significantly higher among the cases than the controls. PMID: 27943244
  30. SLCO1B1 genotype was not associated with the risk of statin-associated muscle symptoms. PMID: 27595674
  31. these findings demonstrate an important role for OATP1B1 in the systemic pharmacokinetics of multiple drugs used in the treatment of acute myeloid leukemia PMID: 26663398
  32. Genetic link with cholelithiasis among pediatric SCA Tunisian patients: Examples of UGT1A1, SLCO1A2 and SLCO1B1. PMID: 26146896
  33. SLCO1B1 rs113681054, SLCO1B1*5 (rs4149056), CYP3A4*1G (rs2242480), and CYP3A4*5 (rs776746) polymorphisms had no effect on the PK/PD of ticagrelor in healthy Chinese volunteers PMID: 28049954
  34. SLCO1B1 gene variants could affect the pharmacodynamics of rocuronium. PMID: 25279974
  35. Polymorphism of SLCO1B1 c.521 T > C could be a strong predictor of 6-MP dose reduction in maintenance chemotherapy in childhood ALL. PMID: 25939871
  36. No significant difference was observed in the lipid-lowering efficacy of statins between the wild and variant genotypes of SLCO1B1. PMID: 25932441
  37. Patients under pravastatin treatment prior to inguinal hernia repair presented with lower postoperative IL-10 levels with respect to the baseline concentration, regardless of the presence or absence of SLCO1B1 *1 or SLCO1B1 *5 polymorphisms. PMID: 26826613
  38. transport of CPR I mediated by OATP1B1 and OATP1B3 and the transport of CPR III mediated by OATPs 1B1, 1B3 and 2B1 is time-dependent, can be saturated and inhibited PMID: 26383540
  39. The SLCO1B1 rs1104581 polymorphism, weight, and gender appear to play important roles for rifabutin efficiency in African HIV-Infected patients with tuberculosis. PMID: 26482301
  40. Results identified interethnic differences of genetic variations of the SLCO1B1, SLCO1B3, and SLCO2B1 genes in Korean population compared with other ethnic groups. PMID: 26409184
  41. SLCO1B1 variants are strongly associated with an increased risk of enalapril-induced cough. PMID: 26607661
  42. TM11 of OATP1B1 may face the substrate interaction pocket. PMID: 26562723
  43. OATP1B1- and OATP1B3-humanized mice can be used as in vivo tools to assess and possibly predict clinically relevant DDIs. PMID: 26474710
  44. The HEK-293 cell lines stably expressing human OATP1B1-wild and variant (HEK-OATP1B1, *1b and *15) are potential models to study drug transport in vitro PMID: 27455553
  45. Patients with better muscle function had the highest concentration of CK, IL-1, and TNF-a compared with less muscle function PMID: 26380303
  46. the polymorphism rs2306283 at the SLCO1B1 gene determines greater HDL-C concentrations in response to atorvastatin medication in Chilean hypercholesterolemic subjects. PMID: 26334272
  47. Results show ticagrelor pharmacokinetics to be influenced by SNPs in SLCO1B1 though no detectable effects on efficacy or safety were found PMID: 25935875
  48. Down-regulation of OATP1B1/3 proteins may contribute to pathogenesis of jaundice accompanying advanced cholestatic liver diseases. PMID: 26191226
  49. SLCO1B1 and SLCO1B3 polymorphisms contributed to an increased risk of neonatal hyperbilirubinemia. PMID: 26146841
  50. Misoprostol acid was transported across a blood-brain barrier model by MRP4 and SLCO1B1 PMID: 26122863

Show More

Hide All

Involvement in disease
Hyperbilirubinemia, Rotor type (HBLRR)
Subcellular Location
Basolateral cell membrane; Multi-pass membrane protein. Note=Detected in basolateral membranes of hepatocytes.
Protein Families
Organo anion transporter (TC 2.A.60) family
Tissue Specificity
Highly expressed in liver, at the basolateral membranes of centrilobular hepatocytes. Not detected in heart, brain, placenta, lung, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and leukocyte.
Database Links

HGNC: 10959

OMIM: 237450

KEGG: hsa:10599

STRING: 9606.ENSP00000256958

UniGene: Hs.449738

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1